The use of enterosorbents in the immunorehabilitation of patients who have had a new coronavirus infection COVID-19

• Elena P. Tikhonova
• Andrei A. Savchenko
• Tatyana Yu. Kuz'mina
• Yuliya S. Kalinina
• Natalia A. Dyachenko
• Alena A. Masterova
• Vasiliy D. Belenyuk
• Alexandr G. Borisov
• Mikhail A. Popilov

Abstract

Post-covid syndrome is characterized by a spectrum of persistent symptoms that do not disappear for many months, which may be due to an inadequate immune system response. This Leads to a discussion of potentially new methods immunorehabilitation with the use of effective enterosorbents.

The aim of the study was to assess the dinical effectiveness of enterosorbents and immunological parameters of patients with a long-term "post-covid syndrome" who have undergone a new coronavirus infection COVID-19. In n pilot monitored open non-randomized experimental clinical observationanl study 33 patients who had a novel coronavirus infection with COVID-19 underwent comprehensive treatment with the inclusion of azoximer bromide (Polyoxidonium) and colloidal silicon dioxide (Polisorb MP). Analysis of clinical and laboratory data showed that after immunorehabilitation, most of the indicators characterizing the state of the immune system in patients who had COVID-19 were restored to control values. And the use of enterosorbents in complex immunorehabilitation therapy is justified and confirmed by the relief of dyspeptic and asthetovegetative syndromes, which makes it possible to recommend it for use in complex treatment.

Keywords:coronavirus infection, COVID-19, immune system, immunorehabilitation, detoxification, enterosorption

REFERENCES

1. Gudima G.O., Khaitov R.M., Kudlay D.A., Khaitov M.R. Molecular immunological aspects of diagnosis, prevention and treatment of coronavirus infection. Immunologiya [Immunology]. 2021; 42 (3): 198–210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210 (in Russian)

2. Hiscott J., Alexandridi M., Muscolini M., Tassone E., Palermo E., Soultsioti M., et al. The global impact of the coronavirus pandemic. Cytokine Growth Factor Rev. 2020; 53: 1-9.

3. Borisov A.G., Savchenko A.A., Kudryavtsev I.V. Features of the immune response to viral infections. Infektsiya i immunitet [Infection and Immunity]. 2015; 5 (2): 148-56. (in Russian)

4. Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92 (4): 424-32. DOI: https://doi.org/10.1002/jmv.25685

5. Braun J., Loyal L., Frentsch M., Wendisch D., et al. SARS-CoV-2-re-active T cells in healthy donors and patients with COVID-19. Nature. 2020; 587 (7833): 270-4. DOI: https://doi.org/10.1038/s41586-020-2598-9

6. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 324 (8): 782-93. DOI: https://doi.org/10.1001/jama.2020.12839

7. Carfi A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324: 603-5. DOI: 10.1001/jama.2020.12603

8. Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re’em Y., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. MedRxiv. 2020. [Preprint]. DOI: https://doi.org/10.1101/2020.12.24.20248802

9. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397: 220-32.

10. Proal A.D., Van Elzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021; 12: 698169. DOI: https://doi.org/10.3389/fmicb.2021.698169

11. Kozlov V.A., Savchenko A.A., Kudryavtsev I.V., Kozlov I.G., Kud-lay D.A., Prodeus A.P., Borisov A.G., et al. Clinical immunology. Krasnoyarsk: Polikor, 2020: 345 p. DOI: https://doi.org/10.17513/np.438 (in Russian)

12. Giloteaux L., Goodrich J.K., Walters W.A., et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016; 4: 30. DOI: https://doi.org/10.1186/s40168-016-0171-4

13. Newberry F., Hsieh S.Y., Wileman T., Carding S.R. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? Clin Sci. 2018; 132: 523-42. DOI: https://doi.org/10.1042/cs20171330

14. Tikhonova E.P., Kuz’mina T.Yu., Minoranskaya N.S., Kalinina Yu.S., Chernykh V.I. Correction of gastrointestinal manifestations in the new coronavirus infection COVID-19 in elderly patients. Terapiya [Therapy]. 2021; 3 (45): 88-93. DOI: https://doi.org/10.18565/therapy.2021.3.XX-XX (in Russian)

15. Kostinov M.P. Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy. Immunologiya [Immunology]. 2020; 41 (1): 83-93. DOI: https://doi.org/10.33029/0206-4952-2020-41-1-83-91 (in Russian)

16. Kudryavtsev I.V., Subbotovskaya A.I. Experience of measuring the parameters of the immune status using six-color cytofluorimeric analysis. Meditsinskaya immunologiya [Medical Immunology]. 2015; 17 (1): 19-26. DOI: http://doi.org/10.15789/1563-0625-2015-1-19-26 (in Russian)

17. Khaydukov S.V., Baydun L.A., Zurochka A.V., Totolyan A.A. Standardized technology «Study of subpopulation composition of peripheral blood lymphocytes using flow cytofluorimeters-analyzers» (Project). Meditsinskaya immunologiya [Medical Immunology]. 2012; 14 (3): 255-68. DOI: http://doi.org/10.15789/1563-0625-2012-3-255-268 (in Russian)

18. Masselli E., Vaccarezza M., Carubbi C., Pozzi G., Presta V., Miran-dola P., et al. NK cells: a double edge sword against SARS-CoV-2. Adv Biol Regul. 2020; 77: 100737. DOI: https://doi.org/10.1016/j.jbior.2020.100737. PMID: 32773100; PMCID: PMC7292949.

19. Cortinovis M., Perico N., Remuzzi G. Long-term follow-up of recovered patients with COVID-19. Lancet. 2021; 397 (10 270): 173-5. DOI: https://doi.org/10.1016/S0140-6736(21)00039-8

20. Huang C., Huang L., Wang Y., Li X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10 270): 220-32. DOI: https://doi.org/10.1016/S0140-6736(20)32656-8

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)